Nina B. Silverberg, PhD
National Institute on Aging
George Mason University
March 31, 2015



Background on NIH/NIA
National Alzheimer’s Project Act and related
activities
Examples of NIA funded research on:





Cognitive Assessment
Behavior in Neurodegenerative Disease
FTD
Down Syndrome
Resources
Office of the Director
National Institute National Institute
on Alcohol Abuse
on Aging
and Alcoholism
National Institute
of Arthritis and
Musculoskeletal
and Skin Diseases
National Institute on
Deafness and Other
Communication
Disorders
National Institute
of Dental and
Craniofacial
Research
National Institute
of Diabetes and
Digestive and
Kidney Diseases
National Institute
of General
Medical Sciences
National Heart,
Lung, and Blood
Institute
National Institute
of Mental Health
National
Institute of
Biomedical
Imaging and
Bioengineering
National
Institute
on Minority
Health &
Health
Disparities
National
Library of
Medicine
Clinical
Center
National Institute
of Allergy and
Infectious
Diseases
National Cancer
Institute
National Institute
on Drug Abuse
National Institute
of Neurological
Disorders and Stroke
Fogarty
International
Center
National
Center
for
Advancing
Translational
Sciences
Eunice Kennedy Shriver
National Institute
of Child Health
and Human
Development
National Institute
of Environmental
Health Sciences
National
Institute
of Nursing
Research
Center for
Compleme
ntary and
Integrative
Health
National Eye
Institute
National Human
Genome Research
Institute
Center for
Information
Technology
Center for
Scientific
Review
NATIONAL INSTITUES OF HEALTH
National Institute on Aging
Organizational Structure
Office of the Director
Richard J. Hodes, M.D.
Marie A. Bernard, M.D.
Intramural Research
Program
Luigi Ferrucci, M.D.,
Ph.D.
Michele K. Evans, M.D.
Division of Aging
Biology
Felipe Sierra, Ph.D.
Ronald Kohanski,
Ph.D.
Division of
Behavioral and
Social Research
Richard Suzman,
Ph.D.
John Haaga, Ph.D.
Division of Extramural
Activities
Robin Barr, Ph.D.
Chyren Hunter, Ph.D.
Division of Neuroscience
Neil S. Buckholtz, Ph.D.
Creighton Phelps, Ph.D.
Division of Geriatrics
and Clinical
Gerontology
Evan Hadley, M.D.
Winifred K. Rossi,
M.A.
National Alzheimer’s Project
Act (NAPA)

On January 4, 2011, President Barack Obama signed into law the National Alzheimer's Project Act (NAPA), requiring the Secretary of the U.S. Department of Health and Human Services (HHS) to establish the National Alzheimer's Project. The law requires:
o
An annually updated national plan submitted to Congress on how
to overcome Alzheimer’s.
o
Annual recommendations for priority actions to both improve
health outcomes for individuals with Alzheimer’s and lower costs
to families and government programs.
o
The annual evaluation of all federally funded efforts in
Alzheimer’s research, care and services – along with their
outcomes.
o
The creation of an Advisory Council on Alzheimer’s Research,
Care, and Services.
5
Goals
Goal 1: Prevent and Effectively Treat Alzheimer’s Disease by 2025
Goal 2: Enhance Care Quality and Efficiency
Goal 3: Expand Supports for People with Alzheimer’s Disease and Their Families
Goal 4: Enhance Public Awareness and Engagement
Goal 5: Improve Data to Track Progress
6
Research Goals
1.A. Identify Research Priorities and Milestones
1.B. Expand Research Aimed at Preventing and Treating
Alzheimer’s Disease
1.C. Accelerate Efforts to Identify Early and
Presymptomatic Stages of Alzheimer’s Disease
1.D. Coordinate Research with International Public and
Private Entities
1.E. Facilitate Translation of Findings into Medical Practice
and Public Health Programs
Research milestones are available at: http://aspe.hhs.gov/daltcp/napa/milesto
nes/milestones-p.pdf
7
Session 1: Interdisciplinary Approach to Discovering and Validating the Next Generation of Therapeutic Targets for AD
Session 2: Challenges in Preclinical Therapy Development
Session 3: Who to Treat, When to Treat and What Outcomes to Measure
Session 4: Drug Repurposing and Combination Therapy
Session 5: Non‐pharmacological Interventions
A blueprint for an integrated translational research agenda
Session 6: New Models of Public Private Partnerships
Natcher Auditorium, NIH Campus, Bethesda, MD
May 1, 2013 8:00 a.m. 8:05 a.m. 8:25 a.m. 8:30 a.m. 9:30 a.m. 1:15 p.m. May 2, 2013 8:30 a.m. 12:30 p.m. 2:45 p.m. 4:00 p.m. Welcoming Remarks: Story Landis, PhD, Director, NINDS Introduction: Ronald Petersen, PhD, MD, Mayo Clinic Developing Research Recommendations and Timelines for the AD‐Related Dementias Thomas Montine, MD, PhD, Scientific Chair Session 1: Non‐AD and Multiple Etiology Dementias Chairs: Bruce Miller, MD, and David Knopman, MD Session 2: Lewy Body Dementias (LBD, PDD) Chairs: Dennis W. Dickson, MD and Karen S. Marder, MD, MPH Session 3: FTD and AD‐Related Tauopathies Chairs: Michael Hutton, William Seeley Session 4: Vascular Contributions to AD‐Related Dementias Chairs: Steven Greenberg, Berislav Zlokovic Session 5: Health Disparities in AD‐Related Dementias Chairs: Maria Glymour, ScD and Jennifer Manly, PhD Final Panel Discussion and Questions Closed Session: Session Chairs, NIH Leads, Steering Committee ALZHEIMER’S DISEASE RESEARCH SUMMIT 2015:
PATH TO TREATMENT AND PREVENTION February 9–10, 2015 http://www.nia.nih.gov/about/events/
2014/alzheimers-disease-researchsummit-2015
Introductory Remarks Francis Collins (NIH Director) NAPA Research Milestones: Process and Progress Richard Hodes (NIA Director) Plenary Lectures Socioeconomic Burden of AD: Update on National and International Trends Kenneth Langa (University of Michigan) Socioeconomic Burden of AD: Update on Global Trends with a Focus on Developing and Under‐
Developed Countries: Implications for Research Martin Prince (King’s College London) Deconstructing the Complexity of AD David Bennett (Rush University) Session I: Interdisciplinary Research to Understand the Heterogeneity and Multifactorial Etiology of Alzheimer’s Disease Session II: Transforming AD Therapy Development: From Targets to Trials Session III: New Strategies for Prevention Session IV: Innovating Disease Monitoring, Assessment, and Care Session V: Empowering Patients, Engaging Citizens Session VI: Enabling Partnerships for Open Innovation Common Alzheimer’s
Disease Research
Ontology
 Began May 2010
 Collaboration
between NIA and
Alzheimer’s
Association
http://www.nia.nih.gov/researc
h/dn/cadro-outline
International Alzheimer’s
Disease Research
Portfolio
http://iadrp.nia.nih.gov/cadro-web/
The Common Alzheimer’s Disease Research Ontology, (CADRO) is a three‐tiered, dynamic classification system created to capture the complete range of AD research and AD research‐related resources. The first level of classification consists of eight categories: five research, two research resources‐related and one for AD related dementias:








Category A – Molecular Pathogenesis and Physiology of Alzheimer’s Disease
Category B – Diagnosis, Assessment and Disease Monitoring
Category C – Translational Research and Clinical Interventions
Category D – Epidemiology
Category E – Care, Support and Health Economics of Alzheimer’s Disease
Category F – Resources for the Research Community
Category G – Consortia and Public Private Partnerships
Category H – Alzheimer’s Disease‐related Dementias
Research Topic
Research Themes
Each category is divided into “research topics”; many of these topics are further
divided into “research themes” (~225 codes). These research topics and themes will
enable identification of research gaps, areas of overlap/duplication of effort, and
opportunities for collaboration.
IADRP ‐ Tracking AD Research Milestones
Tracking AD Research Milestones
AD Research Milestones linked to CADRO codes
AD Research Milestones linked to funded projects
Community Settings
Diversity
http://projectreporter.nih.gov
PURPOSE: To conduct a randomized
clinical trial assessing the harms and
benefits of screening for dementia
compared to no screening for dementia
among 4,000 older adults cared for in
typical primary care practices.
Pharmacological and non-pharmacologic interventions
Completed and in progress
JAMA 2012
A study of outpatient participants with Alzheimer's disease
or a related dementia who have difficult behaviors that are
upsetting for them or their caregivers. Prazosin is a
medication that is commonly used to treat people with high
blood pressure. Research with prazosin has shown that it
may be effective in treating behavioral problems by
reducing excess adrenalin effects in the brain
Example of repurposing
This study will test the use of venlafaxine to treat the depression in
Alzheimer's Disease (AD). Venlafaxine works by increasing natural
substances in the brain (serotonin and norepinephrine) that help maintain
mental balance. Depression is a very common symptom of AD, affecting as
many as 50% of patients over their illness. Depression in AD contributes
greatly to patient disability and caregiver distress. Venlafaxine is approved
by the U.S. Food and Drug Administration (FDA) for the treatment of major
depression but it is not known whether or not it can help depression in
Alzheimer's Disease.
http://grants.nih.gov/grants/guide/pa-files/PAR-14-089.html
1-800-438-4380
Home Safety for People with Alzheimer's Disease
Sundowning: Alzheimer's Caregiving Tips
Hospitalization Happens: A Guide to Hospital Visits for Individuals with Memory
Loss
Holiday Hints: Alzheimer's Caregiving Tips
Disaster Preparedness: Alzheimer's Caregiving Tips
Bathing: Alzheimer's Caregiving Tips
Alzheimer's Disease Fact Sheet
Driving Safety: Alzheimer's Caregiving Tips
Helping Kids Understand Alzheimer's Disease: Alzheimer's Caregiving Tips
Wandering: Alzheimer's Caregiving Tips
Helping Family and Friends Understand Alzheimer's Disease: Alzheimer's
Caregiving Tips
Hallucinations, Delusions, and Paranoia: Alzheimer's Caregiving Tips
Changes in Communications Skills: Alzheimer's Caregiving Tips
Managing Personality and Behavior Changes: Alzheimer's Caregiving Tips
Rummaging and Hiding Things: Alzheimer's Caregiving Tips
Coping with Agitation and Aggression: Alzheimer's Caregiving Tips
Exercise and Physical Activity: Alzheimer's Caregiving Tips
Caring for a Person with Alzheimer's Disease: Your Easy-to-Use Guide from the
National Institute on Aging
So Far Away: Twenty Questions and Answers About Long-Distance Caregiving
Alzheimer's Disease: Unraveling the Mystery
Guía para quienes cuidan a personas con Alzheimer
End of Life: Helping With Comfort and Care
Thank you!
Questions?